164 related articles for article (PubMed ID: 15118010)
1. Time to stop progesterone receptor testing in breast cancer management.
Olivotto IA; Truong PT; Speers CH; Bernstein V; Allan SJ; Kelly SJ; Lesperance ML
J Clin Oncol; 2004 May; 22(9):1769-70. PubMed ID: 15118010
[No Abstract] [Full Text] [Related]
2. It is not time to stop progesterone receptor testing in breast cancer.
Colomer R; Beltran M; Dorcas J; Cortes-Funes H; Hornedo J; Valentin V; Vargas C; Mendiola C; Ciruelos E
J Clin Oncol; 2005 Jun; 23(16):3868-9; author reply 3869-70. PubMed ID: 15923595
[No Abstract] [Full Text] [Related]
3. Time for reappraisal of progesterone-receptor testing in breast cancer management.
MacGrogan G; de Mascarel I; Sierankowski G; Mauriac L; Debled M; Durand M; De Lara CT; Avril A; Picot V; Mathoulin-Pélissier S
J Clin Oncol; 2005 Apr; 23(12):2870-1; author reply 2871. PubMed ID: 15838009
[No Abstract] [Full Text] [Related]
4. Progesterone receptor testing: not the right time to be buried.
Colozza M; Larsimont D; Piccart MJ
J Clin Oncol; 2005 Jun; 23(16):3867-8; author reply 3869-70. PubMed ID: 15923594
[No Abstract] [Full Text] [Related]
5. Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?
Arnould L; Coudert B; Fumoleau P
J Clin Oncol; 2009 Jun; 27(16):2733; author reply 2734-5. PubMed ID: 19380432
[No Abstract] [Full Text] [Related]
6. Cancer is heterogeneous.
Guinebretiere JM
J Clin Oncol; 2009 Jun; 27(16):2732; author reply 2734-5. PubMed ID: 19380436
[No Abstract] [Full Text] [Related]
7. Prognostic factors for breast cancer and their use in the clinical setting.
Kapoor A; Vogel VG
Expert Rev Anticancer Ther; 2005 Apr; 5(2):269-81. PubMed ID: 15877524
[TBL] [Abstract][Full Text] [Related]
8. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
9. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
Mann GB; Fahey VD; Feleppa F; Buchanan MR
J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
[TBL] [Abstract][Full Text] [Related]
10. [The role of definition of receptor status in the prognosis and the choice of adequate treatment tactics of breast tumors].
Abuladze TZ; Nemsadze GG; Gersamiia GK
Georgian Med News; 2006 Aug; (137):22-4. PubMed ID: 16980736
[No Abstract] [Full Text] [Related]
11. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
12. Insights into the role of progesterone receptors in breast cancer.
Fuqua SA; Cui Y; Lee AV; Osborne CK; Horwitz KB
J Clin Oncol; 2005 Feb; 23(4):931-2; author reply 932-3. PubMed ID: 15681552
[No Abstract] [Full Text] [Related]
13. Isolated tumor cells in bone marrow and its relation with known prognostic factors in breast cancer patients.
Sánchez R; González L; Betancourt L; Rodríguez JJ; Sánchez A; Spinetti D; Parada D; Melone S
Breast J; 2009; 15(2):212-3. PubMed ID: 19292815
[No Abstract] [Full Text] [Related]
14. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
15. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G
Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485
[TBL] [Abstract][Full Text] [Related]
16. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors and therapeutic protocol].
Serment H; Piana L
J Gynecol Obstet Biol Reprod (Paris); 1978 Mar; 7(2):209-20. PubMed ID: 670643
[No Abstract] [Full Text] [Related]
18. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
19. Hormone receptors in defining breast cancer prognosis--time for a rethink?
Speirs V; Shaaban AM
Nat Clin Pract Oncol; 2007 Apr; 4(4):204-5. PubMed ID: 17392711
[No Abstract] [Full Text] [Related]
20. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.
Richter-Ehrenstein C; Müller S; Noske A; Schneider A
Int J Surg Pathol; 2009 Aug; 17(4):323-6. PubMed ID: 19029173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
